Amryt Pharma Holdings Ltd
LSE:AMYT
Amryt Pharma Holdings Ltd
Net Income (Common)
Amryt Pharma Holdings Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amryt Pharma Holdings Ltd
LSE:AMYT
|
Net Income (Common)
-$104.5m
|
CAGR 3-Years
-51%
|
CAGR 5-Years
-103%
|
CAGR 10-Years
N/A
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Net Income (Common)
£4.5B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
AstraZeneca PLC
LSE:AZN
|
Net Income (Common)
$6.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
12%
|
|
Indivior PLC
LSE:INDV
|
Net Income (Common)
$5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Net Income (Common)
$190m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Net Income (Common)
-£27.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Amryt Pharma Holdings Ltd's Net Income (Common)?
Net Income (Common)
-104.5m
USD
Based on the financial report for Dec 31, 2020, Amryt Pharma Holdings Ltd's Net Income (Common) amounts to -104.5m USD.
What is Amryt Pharma Holdings Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-103%
Over the last year, the Net Income (Common) growth was -66%. The average annual Net Income (Common) growth rates for Amryt Pharma Holdings Ltd have been -51% over the past three years , -103% over the past five years .